

FORMULATION AND EVALUATION OF REPAGLINIDE NANOPARTICULATE GEL

Venkat Veerendranadh Yenigalla¹, S. Jeganath^{2*}

Abstract:

The aim of the present work is to formulate and evaluate Repaglinide nanoparticulated gel for topical delivery to reduce blood glucose levels by stimulating endogenous insulin production as a result of decreasing the side effects of Repaglinide by administering the drug topically and to increase the bioavailability of Repaglinide by converting in to nanoparticles. Minimizing the drawback of long term use of Repaglinide by converting in to nanoparticles by solvent/Antisolvent precipitation method and converting in to gel. The prepared nanoparticles will be evaluated for various characterization parameter such asParticle Size Analysis,Zeta potential, FTIR study, Differential Scanning Calorimetry (DSC), Surface Morphology (SEM)Further they are converted in to topical gel by using carbopol 934, HPMC. Evaluation parameters of gel Measurement of PH, Drug content, viscosity study, spreadability, extrudability, homogeneity, grittiness, In-vitro diffusion studies, stability. The formulated topical gel containing Repaglinide nanoparticals can be successfully used to increase the bioavailability of drug and to overcome the side effects.

Keywords: Nanoparticles, Gels, Repaglinide Carbopol 934, Hpmc.

¹Research Scholar, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology And Advanced Studies (VISTAS), Pallavaram, Chennai-600117, India

*Corresponding Author:Dr.S.Jeganath,

Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117,Contact no: +91 9442302356, Email: jeganaths@gmail.com

DOI: 10.48047/ecb/2023.12.si10.00129

Preparation of Repaglinide Nanoparticles

Repaglinide nanoparticles made by using solvent/antisolvent precipitation technique as an successful technique in preparation of nanodrugs. A definite amount of raw drug of repaglinide was totally dissolved in water miscible solvent. Is opropyl alcohol is taken as solvent. According to USP, Categorizing isopropyl alcohol in Class 3. Class 3 consist of no solvent cause human hazard at levels usually accepted in pharmaceuticals. No long-term toxicity or carcinogenicity studies reported for many of the residual solvents in Class 3. The resultant drug solution is then injected into the water consist of surfactant of SLS and/or TEA as stabilizer under stirring at 10000 rpm. Precipitation of solid drug particles occurred immediately upon mixing. The suspension was centrifuged at 5,300 rpm for 10 min and washed twice with purified water¹. In technique, introduction of the drug solution to the anti solvent generates high super saturation. This results in fast nucleation rate and produces a large number of nuclei, which reduces the solute mass for subsequent growth. Nanoparticles can thus be obtained provided that the growth of nucleating crystals can be arrested by the stabilizer (surfactant or polymer) through steric or electrostatic mechanism. The effect of SLS and TEA is studied on precipitated repaglinide particle

size. The supersaturated drug was injected to separate solutions of SLS and TEA in water with concentrations of 0.1, 0.2, 0.3, 0.4 and 0.5 % w/v. The best results were obtained on 0.5 ratio of SLS and TEA, due to both static and electrostatic activity of them. Therefore, SLS/TEA surfactant pair is a crucial way to obtain repaglinide nanoparticles in 43 - 300 nm².

Preparation of nanoparticulate gel

Topical gel of repaglinide nanoparticles where prepared by using Carbopol 934, Sodium alginate and HPMC as gelling agent, propylene glycol and water as dispersed phase. Gels where formed by using three different concentration of various gelling agents carbopol934, Sodium alginate and by keeping the concentration of HPMC repaglinide and other ingredients constant³. The solvent system is made by dissolving water and propylene glycol 80:20 ratio. The required quantity of Carbopol-934, Sodium alginate and HPMC are taken and mixed into 100ml of solvent system and stirred it for 3 hours to get the uniform solution. The quantity of nanoparticles equivalent to 100mg of repaglinide was weighed and dissolved in to the above Carbopol 934, Sodium alginate and HPMC solution and stirred for 12 hours for uniform distribution⁴.

Ingredients	Formulation code									
	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10
Repaglinide nanoparticles	100mg	100mg	100mg	100mg	100mg	100mg	100mg	100mg	100mg	
Carbopol-934	0.5g	1g	1.5g	-	-	-	-	-	-	
Sodium alginate	-	-	-	0.5g	1g	1.5g	-	-	-	-
HPMC	-	-	-	-	-	-	0.5g	1g	1.5g	
Carbopol- 934,Sodium alginate & HPMC	-	-	-	-	-	-	-	-	-	1.5 g
Propylene glycol	10ml	10ml	10ml	10ml	10ml	10ml	10ml	10ml	10ml	10ml
Water	90ml	90ml	90ml	90ml	90ml	90ml	90ml	90ml	90ml	90ml

Preformulation study:

Preformulation study's are one of the important process of optimizing the formulation of novel dosage form. Science preformulation affect drug performance and efficacious, safe and stable dosage form. Various preformulation studies which were carried out are discussed in the following sections

Identification Tests Determination of Melting Point

Melting point determination of the drug sample has been done by open capillary method. Thedrug which has been taken in the glass capillary in which one end was sealed by flame. Inthis method capillary tube was sealed with gentle heating from one end. Then the small quantity of repaglinide was filled in to the small capillary. Capillary was tied in such a way that the tube containing repaglinide was dipped in to the oil phase in such a way that the sealed part of the capillary containing repaglinide was dipped into the oil. Gently the oil bath was heated. As soon as the powder starts melting, the heating was stopped and the temperature was noted down⁵

Compatibility Studies by IR-Spectroscopy

Compatibility is one of the most important factor which affect the stability of the product. FT-IR spectroscopy used to ensure compatibility between polymer and drug. The FT-IR spectra of the drug with polymers were compared with the standard FT-IR spectrum of the pure drug. For determining the compatibility of drug with polymers, IR spectra of pure repaglinide, pure polymer like carbopol-934,HPMC,physical mixture of drug and polymer was taken⁶

Differential Scanning Calorimetry (DSC)

Differential scanning calorimetry (DSC) was performed on DSC 131 SETARAM. The samples equilibrated at 20°C for 30 min. Indium standard was utilized to adjust the DSC temperature and enthalpy scale. The powder samples were hermetically sealed in aluminum pans and heated at a continuous rate of 3°C/min, over a temperature series of 20– 170 °C. Inert atmosphere was conserved by purging nitrogen at the flow rate of 15.8 ml/min, linear velocity 35 cm/sec and pressure 24.7 kPa.

Evaluation parameters of gel a) Measurement of P^H

 P^{H} is measured by digital P^{H} meterEg- 1g of gel mixed in 100 ml distilled water and kept for 2 hrs. Measurement of P^{H} in triplicate and calculate average value.

b) Drug content

1g of gel dissolved in 100 ml of appropriate solvent stoke solution has been filled. The prepared aliquers of various concentration by using suitable dilution and absorbance is measured. To calculated drug content linear regression analysis of calibration curve can be used⁷.

c) Viscosity study

Brook field viscometer is utilized for its examination turn the gels at 0.3, 0.6 and 1.5 Rpm. Relating dial perusing are been noted at each speed. Consistency was gotten by dial perusing X factor given the brook field viscometer inventories

d) Spreadability

It demonstrate the degree of territory to which gel promptly spreads on application to the skin or influenced part. The therapeutic potency is depended on spreading value. The time in sec taken by two slides to sneak off from gel which is set in the middle of the slides towards the heading of certain lead is spreadability less time taken better spreadability. It tends to be determined by utilizing the equation⁸

Spreadability $[s] = M \times L/T$ Where

M = weight tied to upper slide

L= length of glass slides

T = time taken to separate the slides.

e) Extrud ability studies

Formulations are packed in collapsible tubes before set inside the container. This is determined in terms of weight in gm required to extrude a 0.5 cm ribbon at gel in 10 second.

f)Homogeneity

Visual examination is done to find homogeneity fill gel in a container and tested for appearance and existence of any aggregated⁹

g) Grittiness

Light microscope is used formulations were evaluated microscopically to find if there is presence of any visible particulate matter

h) In-Vitro diffusion studies

It is carried out by Franz diffusion cell, for studying dissolution release of gel through a cellophane membrane. 0.5 of gel taken in cellophane membrane. Diffusion studies carried out at $37\pm1^{\circ}$ c using 250ml P^H buffer(P^H 7.4) as the dissolution medium^{10,11}

Stability Studies:

Stability of a drug has been defined as the stability of a particular formulation, in a specific container, to remain within its physical, chemical, therapeutic and toxicological specifications throughout its shelf life

As per ICH guidelines Stability studies were carried out at 30 °C / 60% RH, 40 °C / 75% RH for the selected formulations for 60 days and evaluated for their drug content and in vitro dissolution study¹².

Compatability studies:

The FTIR spectroscopic studies were carried out for standard repaglinide, carbopol 934, HPMC and mixture of repaglinide- carbopol 934, repaglinide-HPMC and repaglinide- carbopol 934-HPMC by KBr pellet technique using FTIR spectrophotometer. The FTIR spectrum of standard is compaired with that of mixture and found that there is no interference.

Results and discussion

Formulation code	C-H stretching	COOH stretching	CH ₃ Bending	C-O stretching
Pure drug	2955.40	1720.73	1416.96	1268.42
Formulation	2956.08	1718.74	1420.21	1266.99

Major peaks of FT-IR Spectra




Figure 1: FTIR spectrum for carbopol 934




Figure2:FTIR spectrum for HPMC




Figure3:FTIR spectrum of repaglinide




Figure4:FTIR spectrum of carbopol 934+Drug




Figure5:FTIR spectrum of HPMC+Drug





Figure6:FTIR spectrum of carbopol 934+HPMC+Drug

Differentialscanning calorimetry:

Thermal behaviour of repaglinide & formulation was studied using DSC to observe the effect of polymer on repaglinide



Characterization of Nanoparticles:

Measurement of particle size of Nanoparticles

The particle sizes of nanoparticles were measured using microphotograph of 100 particle size range from 160 to 405 nm for various batches.

S.NO	FORMULATION	PARTICLE SIZE					
1.	F1	405					
2.	F2	320					
3.	F3	311					
4.	F4	215					
5.	F5	187					
6	F6	185					
7	F7	160					
8	F8	330					
9	F9	275					
10	F10	350					


Zeta potential:

Table 4: Zeta potential of Nanoformulation

S.NO	FORMULATION	ZETA POTENTIAL(mv)
1.	F1	17.0
2.	F2	17.3
3.	F3	18.0
4.	F4	18.8
5.	F5	20.0
6	F6	12.5
7	F7	11.9
8	F8	15.7
9	F9	16.4
10	F10	18.2

Scanning electron microscope (SEM):

SEM analysis of the prepared formulation was carried out to understand the morphology of Nanoparticles. In the SEM images indicates that the nanoparticles were discrete, uniform and spherical with a smooth surface. Hence the images show that proper expected shape has been achieved.



Preparation and Evaluation of topical gel containing repaglinide nanoparticles

Based on the result of the particle size and SEM images the best formulation F5 was selected and further converted in to topical gel. Topical gels where prepared by using nanoparticles containing equivalent to 100mg repaglinide, carbopol 934, HPMC, propylene glycol and water

Measurement of pH

The pH values of formulated gel ranges from 6.4-7.1. Which is suitable for applying to skin and minimise irritation.

Drug Content

The drug content estimated for formulated gel. The drug content showed that the drug was distributed uniformly throughout the gel

Percentage Yield and Viscosity

Percentage yield of topical gel containing repaglinide was in range of 95.43-98.87%. It was

found that the percentage yield of F10formulation has larger % yield than other formulations. Generally consistency of formulation relies upon on the ratio of solid fraction to liquid fraction which produces gel structure.

Spreadability

It is measured as a important factor that shows gelcharacter which comes out from tube. For all the formulations spreadability test is carried of. With respect to increase in the polymer concentration spreadability of the gel formulation decreases

Homogenecity

Visual examination is done to ensure the syneresis and colour of the prepared gel. The gel must be clear and transparent. The formulated gel are found to be good homogeneity without any lumps and syneresis.

Table 5.nH	Spraadability	and Drug co	ntant of Forn	nulations (F1-F5)	
Table 5:pri,	Spreauability	and Drug co	піені оі гогн	IUIALIOIIS (Г1-ГЭ)	

Formulation code	рН	Spredability (gm.cm ²)	Drug content %
F1	6.5	11.00	95.32 ± 0.012
F2	6.6	11.08	96.32± 0.012
F3	6.8	11.75	97.43 ± 0.024
F4	6.9	10.25	96.01 ± 0.018
F5	7.1	10.75	98.67 ± 0.021
F6	6.5	11.07	94.13±0.212
F7	6.6	10.95	95.75±0.154
F8	6.4	11.35	97.89±0.013
F9	6.7	11.56	99.54±0.021
F10	7.0	10.85	97.45±0.012

Table 6: Percentage Yield and Viscosity of different formulations (F1-F10)

Formulation code	Viscosity(centipoises)	Percentage yields %
F1	4502	96.80
F2	4321	95.90
F3	3321	97.87
F4	3741	97.01
F5	2431	98.10
F6	3642	97.20
F7	4523	96.54
F8	4321	95.43
F9	4123	96.56
F10	3632	98.43

In vitro diffusion

Diffusion cell are used to find drug release profile of repaglinide nanoparticulated topical gel formulations. the graphical representation is shown in Fig .7 &8.The percentage drug release of all formulations after 4.5 hours using carbopol 934,HPMC,and sodium alginate combination was found to be 83.80 %(F1), 78.96% (F2), 85.70%(F3) and 75.20% (F4), 89.98% (F5) ,F6 (91.03%), F7(89.51%),F8(85.92%)F9(85.21) & F10(87.21) respectively. The most important factors in the drug release is the type of polymer and the concentration of polymer

S.NO	TIME	%DRUG RELEASE						
		F1	F2	F3	F4	F5		
1.	30	11.45	9.54	10.15	8.90	10.96		
2.	60	22.79	17.07	21.50	14.06	25.56		
3.	90	35.41	23.91	35.01	24.55	38.12		
4.	120	47.33	35.44	49.02	38.23	52.23		
5.	150	64.21	49.71	61.25	49.10	64.45		
6.	180	70.39	59.23	68.09	55.18	75.07		
7.	210	75.06	69.11	73.99	64.10	80.02		
8.	240	80.05	73.86	80.52	72.24	84.14		
9.	270	83.80	78.96	85.70	75.20	89.98		

 Table 7: Comparative Dissolution Study of Different Formulations




Figure 9: %Comparative Dissolution Study of Different Formulations (F1-F5)

	Time(mts)	% Drug R	% Drug Release						
S. No.		F6	F7	F8	F9	F10			
1	30	4.34	3.24	3.12	3.56	4.67			
2	60	8.64	8.15	7.32	6.64	9.54			
3	90	17.25	15.38	16.38	14.32	13.78			
4	120	27.13	26.43	25.05	24.11	25.76			
5	150	39.06	38.06	37.62	34.84	35.21			
6	180	56.52	54.43	57.06	51.92	55.67			
7	210	67.25	64.79	63.96	65.29	66.32			
8	240	82.85	78.29	75.09	73.55	76.14			
9	270	91.03	89.51	85.92	83.21	87.25			

Table 8: Comparative in vitro drug release of different formulations

Stability studies:

Stability studies of the prepared formulations were carried out by storing the optimized formulation F9 at $30 \pm 2^{\circ}$ C& $60 \pm 5^{\circ}$ RH and $40 \pm 2^{\circ}$ C& $75 \pm 5^{\circ}$ RH for 60 days. Two parameters namely

percentage Drug content and *in-vitro* release studies were carried out. It was observed that there was no change in drug content and invitro drug release profile even after storage at $30 \pm 2^{\circ}C\&$ 60 $\pm 5\%$ RH and $40 \pm 2^{\circ}C\&$ 75 $\pm 5\%$ RH for 60 days.

 Table 9: Invitro drug release studies After Storing At Different Temperatures (F9)

	Time(hrs)	0 Days	Percentage(%) drug release			
S.No			30 days		60 days	
			$30^{0}\pm 2^{0}$ C	$40^{0}\pm 2^{0}$ C	$30^{0}\pm2^{0}$ C	$40^{0}\pm2^{0}$ C
1	30	4.34	3.24	3.12	3.56	4.67
2	60	6.64	6.54	6.51	6.54	5.96
3	90	14.32	14.2	14.15	13.8	13.7
4	120	24.11	24.05	23.9	23.75	23.58
5	150	34.84	34.73	34.65	34.22	33.8
6	180	51.92	51.85	51.72	51.58	51.45
7	210	65.29	65.21	65.05	64.96	64.8
8	240	73.55	73.5	73.38	73.3	73.24
9	270	83.21	83.15	83.08	82.95	82.9

	Drug content	Drug content					
S.No		$30^{0}\pm2^{0}$ C		$40^{0}\pm2^{0}$ C			
		30 days	60 days	30 days	60 days		
1	99.544 ± 0.2	99.38±0.12	99.35±0.08	99.26±0.01	99.20±0.06		

Table 10:Drug Content After Storing At Different Temperatures (F9)

CONCLUSION:

The main objective of the present study was to develop Repaglinide nanoparticulated gel for topical delivery to reduce blood glucose levels by stimulating endogenous insulin production as a result of to increase the bioavailability of Repaglinide by converting in to Nanoparticles. Formulations were prepared and evaluated for physical parameters, drug content, Spread ability Viscosity and diffusion studies. All the parameters are within the limits. Based on the observation it can be concluded that the formulated gel containing Repaglinide can be successfully used to increase the bioavailability of drug and to overcome the side effects of drug.

REFERENCE

- Arti Vashist1, Ajeet Kaushik, Atul Vashist, Rahul Dev Jayant, Asahi Tomitaka1, Sharif Ahmad, Y. K. Gupta, and Madhavan Nair, Recent trends on hydrogels based drug delivery systems for infectious diseases, Biomater Sci. 2016 October 18; 4(11): 1535–1553.
- 2. http://www.slide share.net/Faraza Javed/gel.
- 3. Yang K et al, Antimicrobial hydrogels : promising materials for medical application [pubmed].
- 4. Loyd VA., et al. "Ansel's pharmaceutical dosage forms and drug delivery systems. 9th ed. Philadelphia: Lippincott Williams & Willdns; (2011).
- 5. http://en.wikipedia.org [Internet]. Gel [updated 2014 December 13]. Available from: http://en.wikipedia.org/wiki/Gel.
- 6. Jain N.K. Pharmaceuticals Product Development. CBS Publishers & Distributors Pvt. Ltd. 2006; First edition: 228-230.
- Ghosh, L.K.; Ghosh, N.C.; Chatterjee, M.; Gupta, B.K. Product development studies on the tablet formulation of ibuprofen to improve bioavailability. Drug Dev. Ind. Pharm., 1998, 24, 473477.
- Vasconcelos, T.; Sarmento, B.; Costa, P. Solubility enhancement as strategies to improve oral bioavailability of poorly water soluble drugs. Drug Discovery Today, 2007, 12, 1281-1302.
- 9. Lobenberg, R.; Amidon, G.L. Modern bioavailability and bioequivalence and biopharmaceutics classification system. New scientific approaches to international

regulatory standards. Eur J. Pharm. Biopharm., 2000, 50, 3-12.

- 10.Mosharraf, M.; Nystorm, C.; The effect of particle size and shape on the specific dissolution rate of micronized practically insoluble drugs. Int. J. Pharm., 1995, 122, 35.
 [8] Liversidge, G.G.; Cundy, K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: Absolute oral bioavailability of nanocrystalline Danzol in beagle dogs. Int. J. Pharm., 1995, 125, 91.
- 11.Pavithra k, jeganath s, azeemiqbal (2018) 'Design, development, and characterization of topical gel containing itraconazole - antifungal agent ', *Asian journal of pharmaceutical and clinical research*, 11(4), pp. 153-158.
- 12.P.K. lakshmi*1, markakranthi kumar1, aishwarya sridharan2, shyamala bhaskaran 3, formulation and evaluation of ibuprofen topical gel: a novel approach for penetration enhancement, International journal of applied pharmaceutical sciences, issn- 0975-7058,vol 3, issue 3, 2011.